For in-vitro research use only · Not for human consumption · Not medical advice
The first investigational molecule studied for simultaneously activating GIP, GLP-1, and glucagon receptors — the most comprehensive metabolic agonist profile in current research.
While most metabolic compounds target one receptor, GLP-3R hits three simultaneously — GIP, GLP-1, and glucagon. It's the first investigational molecule to activate all three pathways at once, making it the most comprehensive metabolic compound in research.
Think of your metabolic system as a three-lane highway. Most research compounds only open one lane — GLP-1 agonists, for example, primarily influence insulin secretion and appetite signaling. Dual agonists opened two lanes. GLP-3R opens all three: it activates GLP-1 receptors (insulin and appetite), GIP receptors (beta cell function and nutrient partitioning), and glucagon receptors (energy expenditure and fat oxidation).
The glucagon component is what makes GLP-3R genuinely novel. While it might seem counterintuitive — glucagon raises blood sugar in acute settings — chronic, low-level glucagon receptor activation has been studied for increasing resting energy expenditure and promoting fat oxidation. It's the metabolic equivalent of turning up your thermostat.
Early-phase clinical research has generated significant interest in the scientific community, with researchers noting that the triple-agonist profile produces a more comprehensive metabolic response than single or dual-agonist approaches.
The short version: GLP-3R activates three metabolic receptors simultaneously — GLP-1, GIP, and glucagon. The glucagon component is the novel addition, studied for its ability to increase energy expenditure and fat oxidation on top of the insulin and appetite effects.
Activates GLP-1 receptors studied for their role in insulin secretion, appetite regulation, and gastric emptying — the most well-characterized incretin pathway in metabolic research.
Activates glucose-dependent insulinotropic polypeptide receptors, studied for enhancing beta cell function, improving nutrient partitioning, and potentiating GLP-1 signaling.
The novel addition — activates glucagon receptors studied for increasing resting energy expenditure and promoting hepatic fat oxidation. This is what differentiates GLP-3R from dual agonists.
GLP-3R is the first compound studied for simultaneous activation of all three metabolic receptors (GIP, GLP-1, glucagon), representing a novel pharmacological approach in incretin biology.
The glucagon receptor component has been studied for its contribution to increased resting energy expenditure — a mechanism not present in single or dual agonist compounds.
Early-phase clinical studies have generated considerable research interest, with published data demonstrating a dose-dependent metabolic response across multiple biomarkers.
The glucagon receptor activation component has been specifically studied for its effects on hepatic fat oxidation, a pathway of significant interest in metabolic research.
Not sure where to start? Explore our compound library or take the quiz to discover which research compounds align with your goals.
